Edition:
United Kingdom

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

347.95INR
20 Jul 2018
Change (% chg)

Rs4.40 (+1.28%)
Prev Close
Rs343.55
Open
Rs342.45
Day's High
Rs350.80
Day's Low
Rs332.75
Volume
3,529,076
Avg. Vol
1,357,333
52-wk High
Rs554.90
52-wk Low
Rs332.75

Chart for

About

Cadila Healthcare Limited is an India-based pharmaceutical company. The Company's subsidiaries include Zydus Wellness Limited, Liva Pharmaceuticals Limited, Biochem Pharmaceutical Industries Limited, Zydus Technologies Limited, German Remedies Limited, Dialforhealth India Limited, Dialforhealth Unity Limited and Dialforhealth... (more)

Overall

Beta: 0.50
Market Cap(Mil.): Rs511,564.19
Shares Outstanding(Mil.): 1,023.74
Dividend: 3.20
Yield (%): 0.96

Financials

  CADI.NS Industry Sector
P/E (TTM): 41.67 30.93 32.76
EPS (TTM): 11.99 -- --
ROI: -- 15.07 14.61
ROE: -- 16.60 16.34

BRIEF-Cadila Healthcare Gets Exit Price For Sale Of Shares To Bayer (South East Asia)

* CADILA HEALTHCARE - GOT EXIT PRICE FOR SALE OF SHARES TO BAYER (SOUTH EAST ASIA) PTE LTD IN TERMS OF JV AGREEMENT Source text: http://bit.ly/2HNe3Uu Further company coverage:

02 May 2018

BRIEF-Cadila Healthcare Says Zydus Received Final Approval From USFDA For Bumetanide Tablets USP

* SAYS ZYDUS RECEIVED FINAL APPROVAL FROM USFDA FOR BUMETANIDE TABLETS USP Source text for Eikon: Further company coverage:

02 May 2018

BRIEF-Cadila Healthcare To Sell 12.5 Mln Shares Of JV To Bayer (South East Asia)

* SAYS CO IS SELLING 12.5 MILLION SHARES OF JV TO BAYER (SOUTH EAST ASIA) PTE BY EXECUTING SHARE PURCHASE DEAL Source text - https://reut.rs/2r4g6ft Further company coverage:

27 Apr 2018

BRIEF-Cadila Healthcare Says Zydus Gets U.S. FDA Final Nod For Methylprednisolone Tablets USP, Cinacalcet Hydrochloride Tablets

* SAYS ZYDUS GETS FINAL APPROVAL FROM USFDA FOR METHYLPREDNISOLONE TABLETS USP AND CINACALCET HYDROCHLORIDE TABLETS Source text - http://bit.ly/2Hry5Yw Further company coverage:

25 Apr 2018

BRIEF-Cadila Healthcare Says Zydus Gets Final Approval From U.S. FDA For Diclofenac Sodium Topical Solution

* SAYS ZYDUS GETS FINAL APPROVAL FROM U.S. FDA FOR DICLOFENAC SODIUM TOPICAL SOLUTION

19 Apr 2018

BRIEF-India's Cadila Healthcare Says No Observation Issued For Topical Unit

* SAYS TOPICAL FACILITY SUCCESSFULLY COMPLETES USFDA INSPECTION

28 Mar 2018

BRIEF-Cadila Healthcare Says ‍Zydus Gets U.S. FDA Nod For Metoprolol Succinate Extended-Release Tablets USP​

* SAYS ‍ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR METOPROLOL SUCCINATE EXTENDED-RELEASE TABLETS USP​ Source text - http://bit.ly/2pEyVGd Further company coverage:

26 Mar 2018

BRIEF-Cadila Healthcare Says Zydus Gets Final Nod From U.S. FDA For Tizanidine Tablets USP

* SAYS ZYDUS RECEIVES FINAL APPROVAL FROM U.S. FDA FOR TIZANIDINE TABLETS USP Source text - http://bit.ly/2p5iSkn Further company coverage:

13 Mar 2018

BRIEF-Cadila Healthcare's ‍Zydus Partners With Medicure To Launch Zypitamag In U.S.​

* UNIT ‍ZYDUS PARTNERS WITH MEDICURE TO LAUNCH ITS NDA PRODUCT, ZYPITAMAG (PITAVASTATIN) IN U.S.​ Source text - http://bit.ly/2oYA0Yx Further company coverage:

08 Mar 2018

BRIEF-Cadila Healthcare's ‍Zydus Gets Final Nod From U.S. FDA For Sedative Injection​

* UNIT ‍ZYDUS GETS FINAL NOD FROM U.S. FDA FOR DEXMEDETOMIDINE HYDROCHLORIDE INJECTION

28 Feb 2018

Earnings vs. Estimates